| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-03-09 | BGB-3111 | relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) | 2 | BeiGene (China) | Cancer - Oncology |
| 2017-03-06 | volanesorsen (ISIS-APOCIII Rx) | familial chylomicronemia syndrome | 3 | Ionis Pharmaceuticals (USA - CA) Akcea Therapeutics (USA - MA) | Rare diseases - Genetic diseases - Metabolic diseases |
| 2017-03-06 | SD-101 and Keytruda® (pembrolizumab) | metastatic melanoma | 1b-2 | Dynavax (USA - CA) | Cancer - Oncology |
| 2017-03-06 | M1095 | psoriasis | 1b | Merck KGaA (Germany) | Autoimmune diseases - Dermatological diseases |
| 2017-03-06 | SGN-CD33A (vadastuximab talirine) | relapsed or refractory acute myeloid leukemia (AML) | 1-2 | Seattle Genetics (USA - WA) | Cancer - Oncology |
| 2017-03-04 | Taltz® (ixekizumab) | plaque psoriasis | 3 | Eli Lilly (USA - IN) | Autoimmune diseases - Dermatological diseases |
| 2017-03-03 | TG4010 and Opdivo® (nivolumab) | metastatic non-small-cell lung cancer (NSCLC) | 2 | University of California, Davis, (USA - CA) Transgene (France) BMS (USA - NY) | Cancer - Oncology |
| 2017-03-03 | guselkumab (CNTO 1959) | psoriasis | 3 | Janssen Research & Development, a J&J company (USA - NJ) | Autoimmune diseases - Dermatological diseases |
| 2017-03-02 | Alprolix® (eftrenonacog alfa - long-lasting recombinant Factor IX Fc fusion protein (rFIXFc) - BIIB 029 | hemophilia B | 3 | Bioverativ (USA - MA) Swedish Orphan Biovitrum SOBI (Sweden) | Hematologic diseases - Genetic diseases - Rare diseases |
| 2017-03-02 | BGB-3111 | relapsed or refractory mantle cell lymphoma | 2 | BeiGene (China) | Cancer - Oncology |
| 2017-03-02 | Translarna™ (ataluren) | nonsense mutation cystic fibrosis (nmCF) | 3 | PTC Therapeutics (USA - NJ) | Rare diseases - Genetic diseases |
| 2017-03-02 | CHS-1420 (biosimilar version of Humira® (adalimumab)) | Coherus Biosciences (USA - CA) | |||
| 2017-03-01 | voclosporin | lupus nephritis | 2b | Aurinia Pharmaceuticals (Canada) | Autoimmune diseases – Inflammatory diseases - Renal diseases |
| 2017-03-01 | Crigler-Najjar Syndrome | Audentes Therapeutics (USA - CA) | Hepatic diseases - Liver diseases | ||
| 2017-03-01 | STR001 (pioglitazone) | hearing loss, preservation of residual hearing in patients undergoing cochlear implantation surgery | preclinical | Strekin (Switzerland) | Otorhinolaryngology |
| 2017-03-01 | STR001 (pioglitazone) | preservation of residual hearing in patients undergoing cochlear implantation surgery | 2 | Strekin (Switzerland) | Otorhinolaryngology |
| 2017-02-28 | radezolid | mild-to-moderate acne | 1 | Melinta Therapeutics (USA - CT) | Dermatological diseases |
| 2017-02-28 | C3 glomerulopathy | natural history | Achillion Pharmaceuticals (USA - CT) Imperial College London (UK) | Rare diseases - Renal diseases - Kidney diseases | |
| 2017-02-28 | resminostat (oral pan-histone deacetylase (HDAC) inhibitor) | advanced-stage cutaneous T-cell lymphoma (CTCL) | preclinical | 4SC (Germany) | Cancer - Oncology |
| 2017-02-27 | ORY-2001 | multiple sclerosis | preclinical | Oryzon Genomics (Spain) | Neurodegenerative diseases |
